{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007158","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.995634+00:00","generated_at":"2026-06-16T06:23:28.713838+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kala subsidiary awarded $15M CIRM grant for KPI-012 PCED Phase 2b trial","bullets":["CIRM awarded Combangio a $15M grant to support KPI-012 for persistent corneal epithelial defect.","Grant funds the CHASE Phase 2b trial, product characterization, and analytical development.","Part of the award is upfront; remainder upon achieving specified milestones.","Combangio must meet a co-funding requirement; Kala committed to provide necessary funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007158","json":"https://secwatch.observer/filing/0001558370-23-007158.json","markdown":"https://secwatch.observer/filing/0001558370-23-007158.md","text":"https://secwatch.observer/filing/0001558370-23-007158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023007158/0001558370-23-007158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023007158/kala-20230428x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:23:28.713838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}